Forskellen i den samlede overlevelse viste en stærk klinisk forskel (p=0, 029, log rank test stratificeret ved center): overlevelsesrater på 53 måneder var 80, 9% for patienter i R- CVP- gruppen i forhold til 71, 1% for patienter i CVP- gruppen.
The difference between the treatment groups with respect to overall survival showed a significant clinical difference (p=0.029, log-rank test stratified by center): survival rates at 53 months were 80.9% for patients in the R-CVP group compared to 71.1% for patients in the CVP group